Physician profile
Matthew D Deshazo
NPI 1518178441
$37,605.66
in general payments reported to CMS, 2019-2025
17 companies · $5,274 in 2025
The $5,274 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,115 · 2020: $1,731 · 2021: $3,116 · 2022: $136 · 2023: $8,706 · 2024: $14K · 2025: $5,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $1,521 · Travel and Lodging: $657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,330.00 |
| Food and Beverage | $1,520.88 |
| Travel and Lodging | $656.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $21,175.90 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $5,847.77 | 2019-2025 | |
| Lilly USA, LLC | $5,822.49 | 2023-2025 | Jardiance |
| Gilead Sciences, INC. | $2,467.21 | 2019 | |
| Abbott Laboratories | $1,508.02 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Abiomed | $161.04 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $103.30 | 2022-2025 | Winrevair |
| United Therapeutics Corporation | $100.00 | 2020 | |
| Medtronic, INC. | $99.58 | 2021 | |
| Novartis Pharmaceuticals Corporation | $72.76 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $71.77 | 2023-2025 | Camzyos |
| Actelion Pharmaceuticals US, INC. | $61.18 | 2022-2024 | Opsumit, Uptravi |
| Novo Nordisk INC | $39.51 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Medtronic Vascular, INC. | $25.82 | 2020 | |
| Cvrx, INC. | $25.75 | 2024 | Barostim Neo System |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14.41 | 2023 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $9.15 | 2020-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Deshazo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.